June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...

Recent media reports from Pakistan suggest that Imran Khan, the former Prime Minister and World Cup-winning captain, has reportedly lost nearly 85% of vision in his right eye due to central retinal ...

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...

The market battle between Roche’s Vabysmo and Regeneron and Bayer’s Eylea just cranked up a notch. With Vabysmo’s FDA approval to treat retinal vein occlusion (RVO), the rival eye meds share another ...